Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.

@article{HrslevPetersen2014AdalimumabAT,
  title={Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.},
  author={Kim H\orslev-Petersen and Merete Lund Hetland and Peter Junker and Jan P\odenphant and Torkell Ellingsen and Palle Ahlquist and Hanne Merete Lindegaard and Asta Linauskas and Annette Schlemmer and Mette Yde Dam and I J Hansen and Hans Christian Horn and Christian Gytz Ammitzb\oll and Anette F B J\orgensen and Sophine B. Krintel and Johnny Raun and Julia Sidenius Johansen and Mikkel \Ostergaard and Kristian Stengaard-Pedersen},
  journal={Annals of the rheumatic diseases},
  year={2014},
  volume={73 4},
  pages={654-61}
}
OBJECTIVES An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP<3.2) at 12 months. METHODS In 14 Danish hospital-based clinics, 180 disease-modifying anti-rheumatic drugs (DMARD)-naïve ERA patients (<6 months duration) received… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Similar Papers

Loading similar papers…